Fig. 4From: Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomesGraphs showing mean number of days requiring triptans, and requiring painkillers (simple or opiate analgesics), before and after commencing erenumab. Three months of baseline data (month 0, 1, 2) is followed by 9 months of post-treatment data (month 3–11). Error bars represent standard error of the meanBack to article page